FSD Pharma Statistics
Total Valuation
FSD Pharma has a market cap or net worth of $18.87 million. The enterprise value is $11.34 million.
| Market Cap | 18.87M |
| Enterprise Value | 11.34M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
FSD Pharma has 40.44 million shares outstanding. The number of shares has increased by 2.21% in one year.
| Shares Outstanding | 40.44M |
| Shares Change (YoY) | +2.21% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 17.37% |
| Owned by Institutions (%) | 2.53% |
| Float | 34.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.96 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.43 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -59,872.51 |
Financial Efficiency
Return on equity (ROE) is -111.10% and return on invested capital (ROIC) is -175.23%.
| Return on Equity (ROE) | -111.10% |
| Return on Assets (ROA) | -82.00% |
| Return on Capital (ROIC) | -175.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$791,781 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.30% in the last 52 weeks. The beta is 0.91, so FSD Pharma's price volatility has been similar to the market average.
| Beta (1Y) | 0.91 |
| 52-Week Price Change | -69.30% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 17.40 |
| Average Volume (30 Days) | 140,295 |
Short Selling Information
The latest short interest is 333,369, so 0.82% of the outstanding shares have been sold short.
| Short Interest | 333,369 |
| Short Previous Month | 436,573 |
| Short % of Shares Out | 0.82% |
| Short % of Float | 0.97% |
| Short Ratio (days to cover) | 1.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.30M |
| Pretax Income | -13.02M |
| Net Income | -13.46M |
| EBITDA | -11.19M |
| EBIT | -13.02M |
| Earnings Per Share (EPS) | -$0.33 |
Balance Sheet
The company has $7.78 million in cash and $246,609 in debt, giving a net cash position of $7.53 million or $0.19 per share.
| Cash & Cash Equivalents | 7.78M |
| Total Debt | 246,609 |
| Net Cash | 7.53M |
| Net Cash Per Share | $0.19 |
| Equity / Book Value | 9.62M |
| Book Value Per Share | 0.24 |
| Working Capital | 4.74M |
Cash Flow
| Operating Cash Flow | -7.87M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.87M |
| FCF Per Share | -$0.20 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FSD Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.21% |
| Shareholder Yield | -2.21% |
| Earnings Yield | -71.32% |
| FCF Yield | -41.71% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 16, 2019. It was a reverse split with a ratio of 1:201.
| Last Split Date | Oct 16, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:201 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |